Sybil Danby, M.S., Director of Business Development joined Paragon in 2016 with 11 years of industry experience across both technical and commercial roles. Prior to joining Paragon Sybil was part of the Single Use Technologies Business Unit at Pall, supporting upstream customers to adopt innovative single-use bioreactor technologies for the production of recombinant proteins, virus-mediated therapies, and whole cell products. Sybil spent 9 years at GSK in both Commercial Manufacturing and Process Development, supporting the development, technology transfer, and manufacture of multiple clinical and commercial monoclonal antibody products. During her time at GSK Sybil developed extensive expertise in the area of bioreactor scaling and cell culture process development, with hands on experience developing and characterizing an upstream process from the bench to 5000L scale for an FDA approved product. Sybil obtained her B.A. in Biology from the University of Rochester and her M.S. in Biology from West Chester University of Pennsylvania.